TY - JOUR
T1 - Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma
AU - Tholey, Danielle M.
AU - Ahn, Joseph
PY - 2015/12
Y1 - 2015/12
N2 - Hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC) incidence in the United States is increasing, partly because of risk factors such as diabetes, fatty liver, hepatitis B virus, and human immunodeficiency virus coinfection. Achieving sustained virologic response (SVR) is the most significant factor in reducing HCV-associated HCC incidence. Improved SVR with the next generation of direct-acting antivirals brings hope for decreased HCC mortality. Nevertheless, surveillance for HCC remains important because HCC can still occur despite SVR, especially in cirrhotics. Individualized risk stratification through increased understanding of HCC pathogenesis and improved surveillance holds the promise for future reduction of HCC incidence.
AB - Hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC) incidence in the United States is increasing, partly because of risk factors such as diabetes, fatty liver, hepatitis B virus, and human immunodeficiency virus coinfection. Achieving sustained virologic response (SVR) is the most significant factor in reducing HCV-associated HCC incidence. Improved SVR with the next generation of direct-acting antivirals brings hope for decreased HCC mortality. Nevertheless, surveillance for HCC remains important because HCC can still occur despite SVR, especially in cirrhotics. Individualized risk stratification through increased understanding of HCC pathogenesis and improved surveillance holds the promise for future reduction of HCC incidence.
KW - Direct-acting antivirals
KW - Hepatitis C virus
KW - Hepatocellular carcinoma
KW - Liver cancer
UR - http://www.scopus.com/inward/record.url?scp=84947615771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947615771&partnerID=8YFLogxK
U2 - 10.1016/j.gtc.2015.07.005
DO - 10.1016/j.gtc.2015.07.005
M3 - Review article
C2 - 26600218
AN - SCOPUS:84947615771
SN - 0889-8553
VL - 44
SP - 761
EP - 773
JO - Gastroenterology Clinics of North America
JF - Gastroenterology Clinics of North America
IS - 4
ER -